Telomere length and cancer risk: finding Goldilocks.
Sharon A SavagePublished in: Biogerontology (2023)
Telomeres are the nucleoprotein complex at chromosome ends essential in genomic stability. Baseline telomere length (TL) is determined by rare and common germline genetic variants but shortens with age and is susceptible to certain environmental exposures. Cellular senescence or apoptosis are normally triggered when telomeres reach a critically short length, but cancer cells overcome these protective mechanisms and continue to divide despite chromosomal instability. Rare germline variants in telomere maintenance genes cause exceedingly short telomeres for age (<ā1st percentile) and the telomere biology disorders, which are associated with elevated risks of bone marrow failure, myelodysplastic syndrome, acute myeloid leukemia, and squamous cell carcinoma of the head/neck and anogenital regions. Long telomeres due to rare germline variants in the same or different telomere maintenance genes are associated with elevated risks of other cancers, such as chronic lymphocytic leukemia or sarcoma. Early epidemiology studies of TL in the general population lacked reproducibility but new methods, including creation of a TL polygenic score using common variants, have found longer telomeres associated with excess risks of renal cell carcinoma, glioma, lung cancer, and others. It has become clear that when it comes to TL and cancer etiology, not too short, not too long, but "just right" telomeres are important in minimizing cancer risk.
Keyphrases
- copy number
- genome wide
- human health
- squamous cell carcinoma
- bone marrow
- acute myeloid leukemia
- dna repair
- renal cell carcinoma
- chronic lymphocytic leukemia
- dna methylation
- mesenchymal stem cells
- papillary thyroid
- risk assessment
- dna damage
- cell death
- endoplasmic reticulum stress
- risk factors
- air pollution
- gene expression
- bioinformatics analysis
- climate change
- allogeneic hematopoietic stem cell transplantation
- radiation therapy
- childhood cancer
- case control
- life cycle